Key result
Direct oral anticoagulants compared with vitamin K antagonists increased the odds of subsequent arterial thrombotic events.
Why the study?
The efficacy and safety of direct oral anticoagulants for patients with thrombotic antiphospholipid syndrome remain controversial.
Do direct oral anticoagulants (DOACs) prevent thrombotic events compared to vitamin K antagonists (VKAs) in patients with thrombotic antiphospholipid syndrome?
Meta-Analysis (n=472)
Open-label
Do direct oral anticoagulants (DOACs) prevent thrombotic events compared to vitamin K antagonists (VKAs) in patients with thrombotic antiphospholipid syndrome?
Answers are grounded in this paper and cite their sources.
In patients with thrombotic antiphospholipid syndrome, DOACs are associated with a significantly increased risk of arterial thrombosis compared to VKAs, supporting the continued use of VKAs in this population.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Khairani et al. (2022) conducted a meta-analysis in Thrombotic antiphospholipid syndrome (n=472). Direct oral anticoagulants (DOACs) vs. Vitamin K antagonists (VKAs) was evaluated on Arterial thrombotic events (OR 5.43, 95% CI 1.87-15.75, p=< 0.001). Direct oral anticoagulants compared with vitamin K antagonists increased the odds of subsequent arterial thrombotic events.
Synapse has enriched 10 related papers. Consider them for comparative context: